Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Schizophrenia

  Free Subscription


10.10.2022

1 Am J Psychiatry
1 J Clin Psychiatry
3 J Clin Psychopharmacol
2 Med J Aust
2 Mol Psychiatry
2 Neuropsychopharmacology
2 Psychiatry Res
3 Psychol Med
1 Schizophr Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Psychiatry

  1. SOLMI M, Taipale H, Holm M, Tanskanen A, et al
    Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.
    Am J Psychiatry. 2022 Oct 6:appiajp21121189. doi: 10.1176/appi.ajp.21121189.
    PubMed         Abstract available


    J Clin Psychiatry

  2. CITROME L, Preskorn SH, Lauriello J, Krystal JH, et al
    Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
    J Clin Psychiatry. 2022;83.
    PubMed         Abstract available


    J Clin Psychopharmacol

  3. JU V, Walkerly A, VandenBerg A, Shobassy A, et al
    New Onset of Seizures and Psychosis in a Patient Who Is Coprescribed Atomoxetine and Bupropion: A Case Report.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00056.
    PubMed        

  4. OKADA T, Hori H, Hasegawa N, Murata A, et al
    Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00057.
    PubMed        

  5. DARWISH M, Bugarski-Kirola D, Passarell J, Owen J, et al
    Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study.
    J Clin Psychopharmacol. 2022 Oct 3. pii: 00004714-990000000-00053.
    PubMed         Abstract available


    Med J Aust

  6. COLES A, Maksyutynska K, Knezevic D, Agarwal SM, et al
    Peer-facilitated interventions for improving the physical health of people with schizophrenia spectrum disorders: systematic review and meta-analysis.
    Med J Aust. 2022;217 Suppl 7:S22-S28.
    PubMed         Abstract available

  7. SHARMA A, Buckhalter S, Siskind DJ, Castle D, et al
    Clozapine shared care: mental health services and GPs working together for better outcomes for people with schizophrenia.
    Med J Aust. 2022;217 Suppl 7:S36-S38.
    PubMed        


    Mol Psychiatry

  8. FIKSINSKI AM, Hoftman GD, Vorstman JAS, Bearden CE, et al
    A genetics-first approach to understanding autism and schizophrenia spectrum disorders: the 22q11.2 deletion syndrome.
    Mol Psychiatry. 2022 Oct 3. pii: 10.1038/s41380-022-01783.
    PubMed         Abstract available

  9. PUVOGEL S, Alsema A, Kracht L, Webster MJ, et al
    Single-nucleus RNA sequencing of midbrain blood-brain barrier cells in schizophrenia reveals subtle transcriptional changes with overall preservation of cellular proportions and phenotypes.
    Mol Psychiatry. 2022 Oct 3. pii: 10.1038/s41380-022-01796.
    PubMed         Abstract available


    Neuropsychopharmacology

  10. LENCZ T, Moyett A, Argyelan M, Barber AD, et al
    Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis.
    Neuropsychopharmacology. 2022 Oct 5. pii: 10.1038/s41386-022-01470.
    PubMed         Abstract available

  11. VINOGRADOV S, Chafee MV, Lee E, Morishita H, et al
    Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity.
    Neuropsychopharmacology. 2022 Sep 30. pii: 10.1038/s41386-022-01451.
    PubMed         Abstract available


    Psychiatry Res

  12. BARLATI S, Nibbio G, Bianchi F, Gigli EBL, et al
    Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.
    Psychiatry Res. 2022;317:114878.
    PubMed         Abstract available

  13. UPTHEGROVE R
    From co-morbidity to transdiagnostic potential and novel immunotherapies for psychosis.
    Psychiatry Res. 2022;317:114866.
    PubMed         Abstract available


    Psychol Med

  14. SARPAL DK, Tarcijonas G, Calabro FJ, Foran W, et al
    Context-specific abnormalities of the central executive network in first-episode psychosis: relationship with cognition.
    Psychol Med. 2022;52:2299-2308.
    PubMed         Abstract available

  15. FAN F, Tan S, Huang J, Chen S, et al
    Functional disconnection between subsystems of the default mode network in schizophrenia.
    Psychol Med. 2022;52:2270-2280.
    PubMed         Abstract available

  16. GUIMOND S, Ling G, Drodge J, Matheson H, et al
    Functional connectivity associated with improvement in emotion management after cognitive enhancement therapy in early-course schizophrenia.
    Psychol Med. 2022;52:2245-2254.
    PubMed         Abstract available


    Schizophr Res

  17. BRUHN D, Hwang S, Howarth A, Dube S, et al
    The burden of illness for patients with schizophrenia and primary negative symptoms: A systematic literature review.
    Schizophr Res. 2022;248:341-344.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: